New data explores CBL-514 in conjunction with GLP-1R therapy for effective treatments.
- Caliway to present at ECO 2026
- Study focuses on CBL-514 and GLP-1R therapy
- Results could inform future treatment strategies
Caliway has announced its participation at the European Congress on Obesity (ECO) 2026, where it will present preclinical data on CBL-514, a novel compound being investigated as a potential treatment. The research focuses on the effects of CBL-514 in combination with GLP-1 receptor (GLP-1R) therapy. This combination aims to enhance treatment options for addressing obesity-related conditions.
The preclinical findings suggest that the combination of CBL-514 and GLP-1R therapy could lead to improved outcomes compared to either treatment alone. This data is expected to provide valuable insights into effective therapeutic approaches for managing obesity and associated metabolic disorders. The presentation at ECO 2026 highlights Caliway’s commitment to advancing research in this important area of health.
Further details on the study methodology and specific results will be shared during the congress, contributing to the scientific dialogue on obesity treatment. As CBL-514 advances through research stages, it is positioned as a promising candidate for clinical evaluation alongside existing therapies.
